Niacin dosing: relationship to benefits and adverse effects.
about
Nutritional properties of the largest bamboo fruit Melocanna baccifera and its ecological significanceNiacin: chemical forms, bioavailability, and health effects.Management of dyslipidemia in women in the post-hormone therapy era.Acute effects of a thermogenic nutritional supplement on cycling time to exhaustion and muscular strength in college-aged menTreating dyslipidemic patients with lipid-modifying and combination therapies.Ocular Effects of Niacin: A Review of the Literature.Extended-release niacin/lovastatin: the first combination product for dyslipidemia.Regulation and deregulation of cholesterol homeostasis: The liver as a metabolic "power station".Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire: results from a randomised placebo-controlled clinical trialCystoid macular edema induced by low doses of nicotinic AcidCrosstalk between poly(ADP-ribose) polymerase and sirtuin enzymes.The role of lipids in the pathogenesis and treatment of type 2 diabetes and associated co-morbidities.Important considerations for treatment with dietary supplement versus prescription niacin products.Plant amino acid-derived vitamins: biosynthesis and function.Effects of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the steady-state pharmacokinetics of digoxin in healthy adult subjects.Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects.Single therapeutic and supratherapeutic doses of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, do not prolong the QTcF interval in healthy volunteers.Opposite effects of nicotinic acid and pyridoxine on systemic prostacyclin, thromboxane and leukotriene production in man.TRPV1 channels are involved in niacin-induced cutaneous vasodilation in mice.Combined effects of niacin and chromium treatment on heart of hyperlipidemic rats.
P2860
Q28833829-8FF0F5B9-26C0-4AE0-BD8E-EE3E715E3EC3Q34278034-9418F3C3-F403-4BA8-B346-E908454ADF38Q34722828-C6826F3F-FCD0-478E-9EF2-B8358336A53AQ34991947-BAC571A3-6F9D-42EF-85BC-F354FC4A2087Q35125390-317C9778-531E-49F8-A8A2-F7BEB685C02BQ35690848-4557CDEE-7135-4D44-A990-3D0A2164A251Q35821875-060C65C8-BC05-4B8D-979B-52ED6714B795Q36071668-BBA1E8FB-1846-412E-943A-BD0FE4CEF695Q36691540-E85FF6E5-21A8-4DC0-AA38-9D743534A040Q36804920-15CCE3E5-98F6-422C-AB4E-2BDE28CC12E4Q36913813-1E04FDD4-28D6-45A7-8EDE-C902CD2CDA61Q37024780-44E90DC5-E0C4-4360-83E9-F30EE0048D5DQ37862929-4FF98E38-0B73-49D0-B9E9-D0707D446CD5Q38173828-E25B5D9A-0CB2-4FD0-B9D4-74CF5A143039Q43144693-70636DA8-DEE5-43A1-ACB4-B736119AC0C1Q43159242-589F9BE8-E002-4A9B-B654-8068F68A740DQ43182514-05551E62-FC15-4064-B799-0B74BBCB3C8EQ44196256-278340F0-B6C3-47FB-BA71-BF357BAD19C9Q48177564-30762172-DC01-4F7A-B3CB-6AA5C16E5BBAQ51526676-BCC2CFBB-61E2-497D-A6AF-389703D19471
P2860
Niacin dosing: relationship to benefits and adverse effects.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Niacin dosing: relationship to benefits and adverse effects.
@ast
Niacin dosing: relationship to benefits and adverse effects.
@en
type
label
Niacin dosing: relationship to benefits and adverse effects.
@ast
Niacin dosing: relationship to benefits and adverse effects.
@en
prefLabel
Niacin dosing: relationship to benefits and adverse effects.
@ast
Niacin dosing: relationship to benefits and adverse effects.
@en
P2093
P2860
P1476
Niacin dosing: relationship to benefits and adverse effects.
@en
P2093
Brusco OA Jr
Capuzzi DM
Intenzo CM
P2860
P2888
P356
10.1007/S11883-000-0096-Y
P577
2000-01-01T00:00:00Z
P6179
1022736819